Neurology News

AstraZeneca announced the ANNEXA phase IV trial assessing the safety and efficacy of andexanet alfa stopped early after achieving prespecified criteria on hemostatic efficacy vs. usual care, according to a press release.

INDIANAPOLIS — In a survey of psychiatrically hospitalized youth, more than half of participants reported their most recent suicide attempt occurred in the evening and night. According to researchers, the diurnal variation in suicidal ideation points to the need for increased support in the later hours of the day to decrease youth suicide risk.

INDANAPOLIS — Circadian disorder is the flagship of sleep-wake disorders, Phyllis C. Zee, MD, PhD, said in her keynote address at the SLEEP meeting.

INDIANAPOLIS — Basic science, through the Sleep Research Society, and clinical care, through the American Academy of Sleep Medicine, have come together at the SLEEP 2023 meeting, June 3-7, here in Indianapolis.

INDIANAPOLIS — Greater variability in sleep duration and sleep onset were risk factors for academic or disciplinary issues among adolescents, according to preliminary research.

CHICAGO — Vorasidenib significantly improved PFS while delaying time to next intervention among certain patients with grade 2 isocitrate dehydrogenase 1- or 2-mutant glioma, according to data presented at ASCO Annual Meeting.

CHICAGO — The escalating prevalence of burnout among U.S. health care providers poses “a real threat” to public health, the U.S. surgeon general told ASCO Annual Meeting attendees.

Medicare will cover drugs that may slow the progression of Alzheimer’s disease if granted traditional approval from the FDA, according to a press release from CMS.

I want to reflect on a recent patient I admitted: a woman in her 40s who presented with an intractable headache.

The FDA has accepted for review a 505(b)(2) new drug application for STS101, a novel, investigational nasal powder for the acute treatment of migraine.